The most relevant news about our Group, in Argentina and around the world.

Sinergium Biotech and a million dollar investment for health

Argentine company Sinergium Biotech, specialized in the research and development of vaccines and biopharmaceuticals, will soon begin construction of a primary antigen production plant in the town of Garín, in the province of Buenos Aires, with an investment of 50 millions of dollars.

With it, once the works are completed in 2019, more than 100 new jobs will be created, Efe sources from the Insud Group, which belongs to this company and which has significant investments in Spain and more than 40 countries, told Efe today.

The new facilities will allow the development of the influenza vaccine in its entirety, as well as others to prevent different diseases, with the same technology that Sinergium Biotech will use for the development of the vaccine against the virus of the Zika “, according to the director of Business of this Company, Fernando Lobos.

The company recently signed an agreement with Protein Sciences Corporation and the Mundo Sano Foundation, closely linked to Insud, for the joint development of a vaccine against the Zika virus.

The productive model of this company allows the transfer and availability of state-of-the-art technologies, the autonomy of Argentina in the production of strategic products that were previously imported, as well as the generation of new sources of qualified work and a significant export potential, according to Businessman Hugo Sigman, shareholder of Sinergium Biotech and CEO of the Insud Group.

Currently, Sinergium Biotech produces the Novartis laboratory technology transfer of influenza vaccine; The pneumococcal conjugate vaccine with technology transfer from Pfizer, the tetravalent vaccine against Human Papillomavirus (HPV), with MSD, and biotech products with mAbxience.

For the president of Sinergium Biotech, Alejandro Gil, it is a pride to continue growing and to be able to start these works to have a plant of these characteristics in Argentina, since very few countries have this type of technology installed.

Located in the town of Garín, in the province of Buenos Aires, the existing plant, next to which will be installed the new one of primary production, has an area of 20,000 square meters and its annual productive capacity reaches 30 million, including Syringes and vials.

Its production process standards are compatible with the highest international standards of good manufacturing practice (GMP), the company said.

The vaccines currently produced by Sinergium Biotech are approved by the National Administration of Medicines, Food and Medical Technology (ANMAT), whose certification is recognized by all South American countries except Brazil, allowing it to be produced and distributed immediately as they occur New orders and in fact allows it to supply all of South America.

It is also certified by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Hugo Sigman said in a statement to this news agency that this laboratory, which produces other vaccines in partnership with multinational pharmaceutical companies, guarantees, due to its production capacity, the needs of the population of Argentina and countries Boundaries in cases of emergency.

(Español) Ver nota completa

Top Story

News Grupo Insud

Silvia Gold: “Las vacunas que más esperanza nos generan son las de vector viral”

Desde el inicio de la pandemia, cuando comenzaron a conocerse las particularidades de este nuevo coronavirus, se supo que la vacuna sería la única salida para que el mundo retome su ritmo, aquel que tenía antes de que el SARS-CoV-2 … Continue reading


Latest News

News Mabxience

Hugo Sigman, sobre la vacuna de AstraZeneca: “Confiamos en que las pruebas serán exitosas”


News Grupo Insud Mundo Sano

El futuro de la pandemia visto por la bioquímica Silvia Gold: “Mucho de lo que aprendimos con dengue, creemos que es lo que hay que hacer con COVID-19″


News Grupo Insud

Hugo Sigman: “El único negocio que tengo con el Estado representa el 1,5% de mi facturación”


News Top Story Grupo Insud

Silvia Gold: “Las vacunas que más esperanza nos generan son las de vector viral”


News Top Story Mabxience

mAbxience: cómo es el laboratorio argentino que va a producir la vacuna de la Universidad de Oxford y AstraZeneca para América Latina


News Inmunova Top Story

ANMAT aprobó estudio clínico en humanos para el suero anti-Covid-19


News Uncategorized

FRESA, el primer proyecto de Grupo Insud en el sector de las energías limpias


News Inmunova

El suero equino hiperinmune obtuvo más de un 90% de eficacia en un grupo de internados en Corrientes